Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study-Reference-Cited by-同舟云学术

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Published:2014-10-02 Issue:14 Volume:124 Page:2196-2202
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Cartron Guillaume¹,de Guibert Sophie²,Dilhuydy Marie-Sarah³,Morschhauser Franck⁴,Leblond Veronique⁵,Dupuis Jehan⁶,Mahe Beatrice⁷,Bouabdallah Reda⁸,Lei Guiyuan⁹,Wenger Michael¹⁰,Wassner-Fritsch Elisabeth¹¹,Hallek Michael¹²

Affiliation:

1. Département d’Hématologie, Unités Mixtes de Recherche–Centre National de la Recherche Scientifique 5235, Centre Hospitalier Universitaire de Montpellier, Montpellier, France;

2. Service d’Hematologie Clinique, Unité d’Investigation Clinique, Institut National de la Santé et de la Recherche Médicale 1414, Centre Hospitalier Universitaire Pontchaillou, Rennes, France;

3. Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital du Haut-Lévèque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France;

4. Service d’Hématologie, Centre Hospitalier Universitaire de Lille, Lille, France;

5. Service d’Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France;

6. Unité Hémopathies Lymphoïdes, Centre Hospitalier Universitaire Henri Mondor, Creteil, France;

7. Département d’Hématologie, Centre Hospitalier Universitaire Nantes, Nantes, France;

8. Centre de Lutte Contre le Cancer Paoli-Calmettes, Marseille, France;

9. Pharma Development Biostatistics, Roche Products, Welwyn Garden City, United Kingdom;

10. Department of Medical Oncology and

11. Pharma Development Oncology, F. Hoffmann–La Roche, Basel, Switzerland; and

12. First Department of Internal Medicine, University of Cologne, Cologne, Germany

Abstract

Key Points In this phase 1/2 study, obinutuzumab (GA101) monotherapy was active in patients with relapsed or refractory CLL. Best overall response was lower in phase 2 vs phase 1, possibly due to higher baseline tumor burden resulting in lower treatment exposure.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/14/2196/1380023/2196.pdf

Reference27 articles.

1. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.;Hallek;Lancet,2010

2. Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label phase II study [abstract].;Hillmen;Blood,2010

3. Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment [abstract].;Foa;Blood,2011

4. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.;Eichhorst;Blood,2009

5. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.;Mössner;Blood,2010

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials;Nature Communications;2024-05-15

2. Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care;Cancers;2024-02-28

3. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

4. Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era;Pharmaceutics;2023-12-29

5. Emerging Therapies in CLL in the Era of Precision Medicine;Cancers;2023-03-03